Authors

Latest:

Dr Randall on the Effect of Socioeconomic Factors in Pediatric Nonmetastatic Osteosarcoma

R. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.

R. Lor Randall, MD, FACS, Huntsman Cancer Institute

R. Michael tuttle, MD, Memorial Sloan Kettering Cancer Center

R. Michael Tuttle, MD, MSKCC

R. Michael Tuttle, MD, MSKCCÂ Â

R. Michael Tuttle, MD, MSKCCÂ Â Â Â

R. Steven Paulson, MD

Latest:

Dr. Paulson on the Importance of Biomarker Testing in Oncology

R. Steven Paulson, MD, discusses the importance of molecular testing in the era of precision medicine in oncology.

R. Wendel Naumann, MD

Latest:

Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Raajit K. Rampal, MD, PhD

Latest:

Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Raajit K. Rampal, MD, PhD Memorial Sloan Kettering Cancer Center

Rachel A. Freedman, MD, MPH

Latest:

Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Rachel E. Rau, MD, Baylor College of Medicine

Rachel Grossman, MD

Latest:

Dr. Grossman Discusses TTFields for Glioblastoma

Rachel Grossman, MD, Neurosurgery Department, Tel Aviv Sourasky Medical Center, discusses tumor treating fields for the treatment of patients with glioblastoma.

Rachel N. Grisham, MD

Latest:

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Rachel Narozniak, MA

Latest:

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Rachel Regn, MD

Latest:

Palliative Care Issues in Gynecologic Cancer

Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.

Rachel Walker, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Rachid Baz, MD

Latest:

Dr Baz on AE Management Discussions in Multiple Myeloma

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Rachna T. Shroff, MD, MS

Latest:

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Rachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma.

Radhakrishnan Ramchandren MD

Latest:

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.